Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06071442 · ClinicalTrials.gov registry record · Phase 1

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

A Phase 1 study, sponsored by Alexion Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target

NCT06071442 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06071442, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target

Study Summary

This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.

Interventions

  • DRUG Metformin
  • DRUG Rosuvastatin
  • DRUG Carbamazepine
  • DRUG Vemircopan
  • DRUG Levonorgestrel / Ethinyl Estradiol

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-01-17
Est. Completion 2024-04-12
Phase Phase 1

Sponsor

Alexion Pharmaceuticals

162 total trials

What the Registry Record Tells You About NCT06071442

The ClinicalTrials.gov registry entry for NCT06071442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.

NCT06071442 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06071442 about?

NCT06071442 is a clinical study titled "Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine". This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.

What is the current status of trial NCT06071442?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-01-17. Estimated completion is 2024-04-12.

What interventions are being tested in trial NCT06071442?

The interventions under investigation include: Metformin (DRUG), Rosuvastatin (DRUG), Carbamazepine (DRUG), Vemircopan (DRUG), Levonorgestrel / Ethinyl Estradiol (DRUG).

Who is sponsoring clinical trial NCT06071442?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.